Fundamentally speaking XOMA is very undervalued at this Price
NO P&D talk just plain looking forward statements . This company is making more moves than APPLE this year so my opinion is straight forward . Enough Cash till the end of 2014 and plenty of positives in 2013 ,lets not forget milestones contracts etc. Nothing wrong with this company other than the undervalued valuation.
I completely agree with you. There are a lot of burned investors / bashers, who for good reason have a dour outlook on XOMA. I've followed the company for years, traded some, lost some and finally threw in the towel a few years ago. But, with the extraordinary Baker Bro's. heavily invested, and who also have top notch personnel on the Board of Directors, the science is finally getting leveraged. Every time it dips to the $2.50 area I can't help but pick up more shares. This one is a good buyout candidate w/i 2-3 years. Gevokizumab will prove to be the money shot for XOMA. From their website: "Based upon its mechanism of action, gevokizumab may also have the potential to address therapeutic needs in cardiovascular disease and other conditions associated with inflammation." As always, there's the potential for adverse medical events to sink the ship, but that's the risk in biotech.